Sedation and Physiological Effects of Intranasal Dexmedetomidine in Severe COPD

Trial Profile

Sedation and Physiological Effects of Intranasal Dexmedetomidine in Severe COPD

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Feb 2017

At a glance

  • Drugs Dexmedetomidine (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions
  • Most Recent Events

    • 12 May 2016 Status changed from recruiting to completed.
    • 02 Nov 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 13 Aug 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top